Skip to content

An exploratory study of apatinib combined with carilizumab in the prevention of postoperative recurrence of liver cancer

An exploratory study of apatinib combined with carilizumab in the prevention of postoperative recurrence of liver cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100049322
Enrollment
Unknown
Registered
2021-07-30
Start date
2021-08-01
Completion date
Unknown
Last updated
2022-04-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hepatocellular carcinoma

Interventions

Case series:None

Sponsors

The First Affiliated Hospital of Anhui Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1.Surgically resected specimens with pathologically proven HCC; 2.Aged 18 to 70 years, male or female; 3.3 weeks after hepatectomy; 4.Patients who meet one of the following risk factors: (1)Preoperative tumor diameter > 5cm; (2)Surgical margin 400 ng/ml; (6)Rupture and hemorrhage of liver cancer; 5.The ECOG 0-2; 6.Child-pugh score: A/B<=7.

Exclusion criteria

Exclusion criteria: 1.Pregnant or lactating female patients; 2.Abnormal coagulation (INR > 1.5 or PROthrombin time (PT) >4 ULN seconds), bleeding tendency or receiving thrombolysis or anticoagulant therapy; Blood coagulation is severely impaired and cannot be corrected; 3.Received molecular targeted drug therapy, radiotherapy, chemotherapy, etc., in addition to apatinib before enrollment; 4.Patients with myocardial ischemia or myocardial infarction of grade II or above, poorly controlled arrhythmias (including QTc interval male >=450 ms, female >=470 ms); 5.Patients with lung and severe renal function abnormalities; 6.Patients who are allergic to any component of Apatinib; 7.Patients with active bleeding; 8.Patients with gastrointestinal ulcer, intestinal perforation or intestinal obstruction; 9.Patients within 30 days after major surgery; 10.Patients with hypertension, whose blood pressure is still poorly controlled after antihypertensive drug therapy (systolic blood pressure > 160 mmHg, diastolic blood pressure > 100 mmHg); 11.Urine routine showed urine protein >=++ or confirmed 24 h urine protein quantity > 1.0g; 12.A history of mental illness or substance abuse.

Design outcomes

Primary

MeasureTime frame
Relapse free survival;

Secondary

MeasureTime frame
Overall survival;Drug safety;

Countries

China

Contacts

Public ContactQian Yeben

The First Affiliated Hospital of Anhui Medical University

15904323577@163.com+86 13956079959

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026